Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12092521
Abstract: Simple Summary Tyrosine kinase inhibitors (TKI) can be safely discontinued in chronic myeloid leukemia patients. Achieving a sustained deep molecular response (DMR) before stop is recommended. Currently, the proportion of patients who achieve a sustained… read more here.
Keywords: cml patients; sustained dmr; deep molecular; dmr ... See more keywords